Neurogenesis drug hits trials

BrainCells, a company that stakes its existence on the once-heretical notion of linkurl:adult neurogenesis,;https://www.the-scientist.com/article/display/12172/ is finally taking its novel treatment for depression into a phase II trial, CEO Jim Schoeneck told me at a neurotechnology meeting in Boston yesterday (May 8). Researchers have recently begun to suspect that treating depression requires neurogenesis. Drugs such as Prozac, though, stimulate nerve growth via the serotonin pathway, which